Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6219720 | 1.00 | AKR1B1 (0.37) | AKR1B1MPI | |
| SCHEMBL19480788 | 1.00 | AKR1B1 (0.37) | AKR1B1MPI | |
| SCHEMBL7153047 | 0.94 | AKR1B1 (0.36) | AKR1B1MPI | |
| SCHEMBL18018688 | 0.92 | AKR1B1 (0.34) | AKR1B1 | |
| SCHEMBL12662797 | 0.86 | — | — | |
| SCHEMBL7150877 | 0.86 | AKR1B1 (0.33) | AKR1B1 | |
| SCHEMBL7150771 | 0.86 | AKR1B1 (0.33) | AKR1B1 | |
| SCHEMBL20833535 | 0.81 | MPI (0.31) | MPI | |
| SCHEMBL7152346 | 0.81 | AKR1B1 (0.36) | AKR1B1MPI | |
| SCHEMBL9789688 | 0.79 | AKR1B1 (0.34) | AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1554299-B1 | NOVEL PENTOSE DERIVATIVES AS ANTI-HYPERGLYCEMIC DRUGS | YISSUM RES DEV CO (IL) | 2013-01-30 | — | — | EP | disclosed |
| US-7812142-B2 | Pentose derivatives as anti-hyperglycemic drugs | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2010-10-12 | — | — | US | disclosed |
| US-20050277599-A1 | Pentose derivatives as anti-hyperglycemic drugs | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277599-A1 | Pentose derivatives as anti-hyperglycemic drugs | SLC2A4, SLC2A1, SLC2A3 | AKR1B1 361/4885MPI 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.